Success During Initial Treatment Period
In addition to efficient administration, efficacy during the acute treatment phase is a critically important feature of a surfactant. Rapidly improved oxygenation, sustained efficacy, and fewer doses can all help wean infants to less invasive forms of ventilation.
Explore 3 features of CUROSURF® (poractant alfa) efficacy that can help you experience fast RDS success:
Rapid onset of action: delivers better short-term efficacy
CUROSURF improves oxygenation within 5 minutes and rapidly reduces FiO2 requirements over the initial treatment period.1,2 It has been suggested that these results may allow you to wean infants off the ventilator sooner.3 As you can see below, infants treated with CUROSURF experienced faster FiO2 reduction than those treated with Survanta® (beractant) over a 6-hour period.3
Physiological end points (eg, faster reduction in FiO2) have not been proven to impact key clinical outcomes such as mortality due to RDS.
Faster reduction in FiO23
- CUROSURF is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes.
Sustained Results with Fewer Doses
CUROSURF demonstrates consistent FiO2 reductions sustained over time 4,5
Respiratory index over first 3 days of life5
- Lower respiratory requirements in the CUROSURF group could be attributed to a greater number of infants extubated at 48 and 72 hours vs Survanta5
- Physiological end points (eg, lower respiratory index) have not been proven to impact key clinical outcomes such as mortality due to RDS
Single-dose success in clinical studies3,6-9
|CLINICAL STUDY||N*||GESTATIONAL AGE||CUROSURF (200 mg/kg)
|Dizdar EA, et al. 20116||106||Median 28 wks||88%|
|Sandri F, et al. 2010 (treatment arm) 7||103||Mean 27.0 ± 1.0 wks||78%|
|Dani C, et al. 2004 8||27||<30 wks||74%|
|Ramanathan R, et al. 2004 3||293||Mean 28.7 ± 2.0 wks||73%|
|Verder H, et al. 1999 9||60||25-29 wks||88%|
- Limited need to redose may decrease the risks associated with reintubation and MV
- Clinical studies have not established that fewer doses result in superior safety or efficacy based on clinically relevant end points